Syntis Bio team (Credit: Syntis Bio)
Exclusive: Bob Langer-founded Syntis Bio gets $33M Series A for obesity, rare disease drugs
A Boston biotech working on a different approach to oral obesity drugs collected a $33 million Series A, with plans to enter the clinic later …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
